NHLBI Director Dr. Gary H. Gibbons spoke with radio host Tom Joyner about asthma during National Asthma Awareness Month. During the 5-minute interview for the Tom Joyner Morning Show, which reaches millions of listeners each week, Dr. Gibbons emphasized important points about asthma, including who it affects, what triggers the disease, and the importance of managing the disease better.
NHLBI Director Dr. Gary H. Gibbons shared his vision for the future of cardiovascular health on his visit to the University of Mississippi Medical Center on March 17-18. He highlighted the importance of funding research, understanding human genetics, utilizing technology and precision medicine, and increasing diversity in biomedical science field. The lecture, “Building on the NHLBI Legacy of Hypertension Research: Charting Our Future Together,” was part of 19th Gertrude and Florian Nelson Cardiovascular Research Lecture.
Harvard Medical School interviews Class of 1984 alumnus Dr. Gary Gibbons about his early influences and his medical career.
Dr. Gary H. Gibbons discusses how his family, exceptional mentors, and educational opportunities combined to launch his scientific career.
Dr. Gary H. Gibbons, director of the NHLBI, and Dr. George Mensah, director of NHLBI’s Center for Translational Research and Implementation Science, co-authored a study published in the Journal of the American Heart Association. The study examined the factors existing at the state level that may influence cardiovascular health outcomes.
NHLBI Director Dr. Gary H. Gibbons recently spoke to medical reporters about the future of individualized medicine and highlighted the role the National Institutes of Health is poised to play in moving this field forward.
On Apr. 5, NIH director Dr. Francis Collins announced the selection of Dr. Gary H. Gibbons as the new director of the NHLBI.
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases. We are intrigued by the promise of new insights into chronic lung disease coming from continuing advances in genetics, the blossoming field of reparative biology, and the applications of new imaging and “omic” technologies in well-characterized patients and populations. These scientific advances embolden us to envision a future in which we challenge the prevailing concept of “chronic lung disease” and contemplate the development of preventive strategies that will preempt the progression to lung disease and/or promote its “remission” toward normal lung physiology and respiratory health.
Gibbons, a leader in work related to cardiovascular health of minority populations, has earned 15 NHLBI-supported grants in the last 15 years and has served on the institute's advisory council since 2009. In an interview with Science Insider, Gibbons said he aims to ensure "that NHLBI continues its legacy of doing discovery science that advances public health."
"The globally recognized research and training supported by the NHLBI continues to advance biomedical knowledge in fields related to heart, lung, and blood diseases," Gibbons said. "I look forward to working with the institute staff and with the many researchers supported by the Institute to foster multi-disciplinary approaches to improve disease prevention, diagnosis, and treatment that will advance the health of all Americans."